Mark G. Eller

Bioavailability of Azacitidine Subcutaneous Versus Intravenous in Patients With the Myelodysplastic Syndromes

Guido Marcucci, Lewis R. Silverman, Mark G. Eller et al. · The Journal of Clinical Pharmacology · 2005 · 147 citations

Sc Administration, Therapeutic Drug Monitoring, Absolute Bioavailability +7

Azithromycin and terfenadine: Lack of drug interaction*

Stuart Harris, Donald M. Hilligoss, Philip M. Colangelo et al. · Clinical Pharmacology & Therapeutics · 1995 · 69 citations

Double-blind Placebo-controlled Study, Pharmaceutical Science, Pharmacological Study +12

Increased Mortality in Narcolepsy

Maurice M. Ohayon, Jed Black, Chinglin Lai et al. · SLEEP · 2014 · 67 citations · Full text

Topical carbonic anhydrase inhibitors

Ronald D. Schoenwald, Mark G. Eller, John A. Dixson et al. · Journal of Medicinal Chemistry · 1984 · 64 citations

Single and multiple dose pharmacokinetics of rifapentine in man: part II.

Anther Keung, Mark G. Eller, K A McKenzie et al. · PubMed · 1999 · 49 citations